Molecular Imaging and Contrast Agent Database (MICAD) has added 17 in vivo molecular imaging and contrast agents to its database, increasing the total to 865 agents.

MICAD was developed by National Center for Biotechnology Information, National Institutes of Health and is an online source of scientific information regarding molecular imaging and contrast agents (under development, in clinical trials or commercially available for medical applications) that have in vivo data (animal or human) published in peer-reviewed scientific journals.

The new PET agents are:

• 124I-A11 which targets prostate stem cell antigen;

• 124I-bm2B3-Db8 which also targets prostate stem-cell antigen;
• [124I]-IMP-R4-ch806 which targets epidermal growth factor receptor deletion variant de2-7;
• 64Cu-PEG27 AVP04-07 which targets tumor-associated glycoprotein 72;
• 64Cu-DOTA-AgRP-7C which targets alpha v beta 3, alpha v beta 5, and alpha 5 beta 1 integrin receptors;
• (R)-[18F]FAMP which targets L-type and A-type amino acid transporter;
• (R)-[18F]NMeFAMP which also targets L-type and A-type amino acid transporter; and
• [18F]MC1-27 which targets mitochondrial complex 1.

The new SPECT agents are:

• [111In]Bomproamide which targets sastrin-releasing peptide receptor;
• [111In]-CHX-A”-DTPA-mAb806 which targets epidermal growth factor receptor deletion variant de2-7; and
• [125I]-mAb806 which targets epidermal growth factor receptor deletion variant de2-7.

The new MRI agents are:

• 17O-labeled water which targets cerebral blood flow; and
• 17O-Oxygen which targets cerebral rate of oxygen consumption and cerebral blood flow.

The new optical agents are:

• Alexa750-ZHER2:342 which targets EGF HER2 receptor; and
• IRDye800-YC-27 which targets prostate-specific membrane antigen.

The new ultrasound agents are:

• PEGylated gold nanoparticles which is non-targeted; and
• SWNT-ICG-RGD which targets alpha v beta 3 integrin.